Response to ASX Query Letter
Filed with ASX · · 7 pages · English
Summary by 6ix AI
Rhythm Biosciences Limited has submitted a response to an ASX query letter regarding its Underwriting Agreement and related termination events. The letter addresses specific questions from the ASX about the execution date of the agreement and the completeness of disclosed termination events. RHY confirms that the Underwriting Agreement remains in full effect and outlines measures taken to ensure compliance with listing rules. The company also acknowledges discrepancies in previous announcements and provides clarifications regarding market-sensitive information.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Rhythm Biosciences Limited on 6ix
Story so far
Earlier from Rhythm Biosciences
- First ColoSTAT Clinical Test Sale
- NATA Accredits ColoSTAT Clinical Testing Service
- RHY Executes SE Asian Genetype Distribution Agreement
- Exercise of RHYO Options underwritten for $4.5m to $6.0m
- Trading Halt
Later from Rhythm Biosciences
- FY26 Appendix 4E & Audited Financial Report
- Initial ColoSTAT Assessment in UK opens new market access
- ColoSTAT Economic Study - Australian Public Health Savings
- Quarterly Activities Report and Appendix 4C
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences